- Peptides are signals, not raw materials. They tell cells what to do rather than supplying what cells are made from — which is why doses are small and specificity is high.
- Sourcing is the whole conversation. The same peptide from a licensed compounding pharmacy and from an online research-chemical vendor are not the same product.
- “Research use only” means not for humans. Those vials carry no purity testing, no sterility assurance and no dose verification — which is exactly why the compounding pathway reopening matters.
- The rules changed in 2026. An FDA advisory committee voted in July to recommend BPC-157, KPV, TB-500, MOTS-c, epitalon and semax for legal compounding — which is about access, not approval.
- Peptides amplify a working system. They are not a substitute for sleep, protein or correcting a deficiency we can measure.
What peptides actually are
A peptide is simply a short chain of amino acids — typically fewer than fifty. Longer chains are proteins. That is the entire distinction.
What makes them interesting therapeutically is that your body already runs on them. Insulin is a peptide. So is glucagon and oxytocin. So, for that matter, is glutathione — your master antioxidant is a tripeptide of glutamate, cysteine and glycine. Peptides are the language cells use to instruct one another, and you are already full of them.
Therapeutic peptides work by speaking that same language. A growth hormone releasing peptide does not supply growth hormone — it signals your pituitary to release more of your own, in your own pulsatile rhythm. That distinction matters enormously for safety and for how the body responds.
Because they are signals rather than substrates, doses are tiny, effects are specific, and the margin between a useful dose and a pointless one is narrower than people expect. Which brings us to the part that actually decides whether any of this works.
Why sourcing decides everything
This is the part of peptide therapy I care most about, and the reason my team will not simply write a prescription for something a patient found online.
Peptides are widely sold online labelled “for research use only, not for human consumption.” That label is not regulatory theatre. It means the vial has not been through purity testing, sterility assurance or dose verification, and the manufacturer is explicitly stating it is not intended to go into a person.
Independent testing of research-grade peptides has repeatedly found products that were under-dosed, over-dosed, degraded, or contained something other than what the label claimed. With a molecule where the effective dose is measured in micrograms, that is not a small problem.
Peptides worth considering are compounded by a licensed 503A pharmacy — which means sterile compounding standards, verified potency, certificates of analysis on every batch, and a pharmacist accountable for what is in the vial. It costs more. It is the only version of this I am willing to put my name to.
“Which pharmacy compounds this, and can I see the certificate of analysis?” A clinic that cannot answer that immediately is a clinic to walk away from. It is the single most useful question in this entire field.
Which peptide for which goal
The peptide chart: what to reach for, by goal
People rarely arrive asking for a specific peptide. They arrive with a goal. This is how those goals map onto the peptides with the most support behind them.
One thing worth saying plainly about this chart: it is a starting point for a conversation, not a menu. Which of these is right for you depends on your history, your medications, your labs and what you are actually trying to change — and for several goals on that list, what I tell patients is that a nutrient deficiency or a sleep problem should be addressed before any peptide is worth considering.
The regulatory picture, and what changed in 2026
This field moved significantly this year, and you deserve an accurate account of where it actually stands.
Peptides sit in several regulatory categories at once, and collapsing them together is how patients get misled.
Some are FDA-approved drugs. Sermorelin and tesamorelin are approved medications with defined indications.
Most sit in the compounding system. In 2023 the FDA moved nineteen widely used peptides into a restricted category, which limited what licensed pharmacies could prepare.
That began to reverse in 2026. In February, HHS Secretary Robert F. Kennedy Jr. announced that roughly fourteen of those nineteen would return to the unrestricted category — including BPC-157, thymosin alpha-1, TB-500, CJC-1295, ipamorelin, GHK-Cu, KPV and MOTS-c. Then in July, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, epitalon and semax to the 503A bulks list, which is the list that governs what a compounding pharmacy may legally prepare.
Two things matter here, and the headlines have not made either of them clear.
First, those votes are advisory and non-binding. The FDA has not issued a final rule, and the formal administrative process is still running. Second, and more importantly: this is about compounding eligibility, not drug approval. None of these peptides has been approved by the FDA as safe and effective for any indication. What changed is the legal pathway for a licensed pharmacy to prepare them on a valid prescription — which matters enormously for sourcing quality, and which is a genuinely different thing from an approval.
The practical effect of the 2023 restriction was that people who wanted these peptides bought them from research-chemical websites instead — unregulated, untested and frequently mislabelled. Restoring a legal compounding pathway moves that demand back into licensed pharmacies with purity testing and accountability. That is a straightforwardly better outcome for patient safety, whatever you think of the underlying evidence.
The ten peptides used most, and what each does
Ranked by how often they are genuinely indicated and how well characterised the mechanism is.
BPC-157
Body Protection Compound-157, derived from a protein found in gastric juice, and the most requested peptide in the field. The preclinical work on tendon, ligament, muscle and gut healing is genuinely striking — it appears to promote angiogenesis and fibroblast migration at the site of injury. Controlled human trials remain limited, and I would rather patients hear that from me. It was among those the FDA advisory committee voted to restore to the compounding list in July 2026.
What the evidence showsBPC-157 promotes angiogenesis and fibroblast migration in tendon, ligament and gut models, with extensive preclinical work by Sikiric and colleagues. An FDA advisory committee voted in July 2026 to recommend it for the 503A compounding list.CJC-1295 with Ipamorelin
The workhorse combination. CJC-1295 is a growth hormone releasing hormone analogue; ipamorelin is a selective secretagogue that triggers release without meaningfully raising cortisol or prolactin. Together they prompt your pituitary to release your own growth hormone in its natural pulsatile rhythm — a very different proposition from injecting HGH directly, and a safer one.
What the evidence showsCJC-1295 and ipamorelin stimulate endogenous growth hormone release in a pulsatile pattern that preserves physiological feedback. Ipamorelin is selective and does not meaningfully raise cortisol or prolactin, unlike earlier secretagogues.Thymosin Alpha-1
One of the best-supported peptides in clinical use anywhere, with decades of study and approval as a pharmaceutical in more than thirty countries for hepatitis B, hepatitis C and as an immune adjunct in oncology. It modulates rather than simply stimulates, which is the property that matters in anyone with autoimmune history.
What the evidence showsThymosin alpha-1 is approved as a pharmaceutical in more than thirty countries for hepatitis B and C and as an immune adjunct in oncology, with decades of clinical use and a substantial immunomodulation literature.TB-500 (Thymosin Beta-4)
Studied for cell migration, angiogenesis and wound healing, and based on a protein present in virtually every cell in your body. Frequently paired with BPC-157 in recovery protocols because the mechanisms complement rather than duplicate each other. Also recommended for compounding restoration in July 2026.
What the evidence showsThymosin beta-4 promotes cell migration, angiogenesis and wound repair in preclinical models and is present in virtually all cell types. It was among those recommended for compounding restoration in July 2026.GHK-Cu
A naturally occurring copper tripeptide with the most substantial research base of anything on this list for skin. It influences a remarkably wide set of genes involved in collagen synthesis, wound repair and antioxidant defence — and levels in human plasma fall by roughly two-thirds between age twenty and sixty. Used topically for skin and hair, and systemically for tissue repair.
What the evidence showsGHK-Cu influences expression of a broad set of genes involved in collagen synthesis, wound repair and antioxidant defence. Plasma levels decline from approximately 200 ng/mL at age twenty to 80 ng/mL at sixty.KPV
A three-amino-acid fragment of alpha-MSH, and one of the most interesting anti-inflammatory peptides available. It acts on inflammatory signalling inside the cell rather than on immune cells from outside, which is why it has been studied particularly in inflammatory bowel conditions and topically in skin. Recommended for the compounding list in July 2026.
What the evidence showsKPV is the C-terminal tripeptide of alpha-MSH and acts on intracellular inflammatory signalling including NF-kB. It has been studied particularly in inflammatory bowel models and topical dermatological application.MOTS-c
A mitochondrial-derived peptide — encoded by mitochondrial DNA rather than nuclear DNA, which is unusual and biologically fascinating. It appears to act on metabolic regulation and insulin sensitivity through AMPK, the same pathway exercise activates. Genuinely one of the more exciting things in this field, and also one of the newest.
What the evidence showsMOTS-c is encoded by mitochondrial rather than nuclear DNA and acts through AMPK — the same pathway activated by exercise and metformin. Preclinical work shows effects on insulin sensitivity and metabolic regulation.Sermorelin and Tesamorelin
The two FDA-approved growth hormone releasing hormone analogues. Sermorelin is shorter acting and the most conservative entry point into this category. Tesamorelin has an approved indication specifically for reducing visceral adipose tissue, with real trial evidence behind it — where visceral fat rather than scale weight is the target, this is the best-supported option.
What the evidence showsSermorelin and tesamorelin are both FDA-approved growth hormone releasing hormone analogues. Tesamorelin has randomised trial evidence for reducing visceral adipose tissue specifically, published in the New England Journal of Medicine.Epitalon
A four-amino-acid peptide studied for effects on telomerase activity and circadian regulation, largely in Russian research. It is simultaneously one of the most interesting things in longevity medicine and one of the least proven in humans. The advisory committee recommended it for the compounding list in July 2026; that is not the same as evidence of efficacy.
What the evidence showsEpitalon has been studied for effects on telomerase activity and circadian regulation, predominantly in Russian research programmes. Western replication remains limited.Selank and Semax
Nootropic and anxiolytic peptides developed in Russia, with a reasonable research base there and limited Western replication. Patients report clarity and reduced anxiety without sedation. Semax was among those recommended for compounding restoration; the evidence base remains thinner than the enthusiasm.
What the evidence showsSelank and semax have a Russian research base for anxiolytic and nootropic effects, with proposed mechanisms involving BDNF and neurotransmitter modulation. Semax was among those recommended for compounding restoration in 2026.What people commonly experience with this therapy
When patients receive the proper guidance, here is what people commonly experience with it.
- Weeks 1–2 — sleep, with growth hormone peptides. Almost always the first change on CJC-1295 with ipamorelin, and a useful early indicator the signalling is working. Growth hormone release is naturally concentrated in deep sleep, and patients describe that phase deepening.
- Weeks 2–4 — recovery. Training soreness resolving faster, and minor nagging injuries beginning to settle. This is where recovery-oriented peptides earn their reputation.
- Weeks 4–12 — body composition and immune resilience. Growth hormone secretagogues shift composition slowly, and that is the correct pace. On thymosin alpha-1, patients typically report fewer minor infections through this window.
- Across a course — measured, not assumed. IGF-1 to confirm growth hormone axis response. hs-CRP where inflammation was the target. Body composition rather than scale weight. A peptide that does not move a number is a peptide worth reconsidering.
If peptides are something you have been considering, let us do it properly. Schedule a consultation and my team will look at what is actually going on underneath, tell you honestly which peptides fit your case, and source them through a licensed pharmacy. World-class care from a team who will tell you when the answer is no.
We will tell you which peptides fit your case, which pharmacy compounds them, and where each one currently stands regulatorily.
Common questions
What is peptide therapy?
Peptides are short chains of amino acids that act as signalling molecules. Therapeutic peptide therapy uses specific ones to prompt particular cellular responses — releasing your own growth hormone, modulating immune function, or supporting tissue repair. They are instructions rather than raw materials, which is why doses are very small and effects are specific.
Are peptides FDA approved?
Some are and some are not, and the distinction matters. Sermorelin and tesamorelin are FDA-approved medications. Most of the others sit in the compounding system, which changed significantly in 2026: in February, HHS announced that roughly fourteen of the nineteen peptides restricted in 2023 would return to unrestricted status, and in July an FDA advisory committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, epitalon and semax for the 503A compounding list. Those votes are advisory rather than final, and importantly they concern compounding eligibility rather than drug approval — none of these has been approved as safe and effective for an indication.
What changed with peptide regulations in 2026?
In 2023 the FDA moved nineteen widely used peptides into a restricted category that limited compounding. In February 2026 HHS Secretary Robert F. Kennedy Jr. announced that around fourteen of them would return to unrestricted status, and in July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend six — BPC-157, KPV, TB-500, MOTS-c, epitalon and semax — for the 503A bulks list. The practical significance is that demand moves back into licensed pharmacies with purity testing rather than research-chemical websites.
Is it safe to buy peptides online?
We would strongly advise against it. Peptides sold online are almost always labelled for research use only, which means no purity testing, no sterility assurance and no dose verification. Independent testing has repeatedly found under-dosed, over-dosed, degraded or mislabelled products. With molecules dosed in micrograms and delivered by injection, that is a serious risk.
What is the difference between CJC-1295 and HGH?
HGH is exogenous growth hormone injected directly, which overrides your own production and carries a different risk profile. CJC-1295 signals your pituitary to release more of your own growth hormone in its natural pulsatile rhythm, with your own feedback loops still intact. That distinction matters both for safety and for how the body responds.
How long before peptides work?
Sleep changes on growth hormone peptides are often noticed within one to two weeks. Recovery effects follow at two to four. Body composition changes take eight to twelve weeks and should be measured rather than eyeballed. Immune-modulating peptides like thymosin alpha-1 work over months rather than weeks.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews. 2018;6(1):45–53. PMC5632578
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612–1632.
- Matteucci C, et al. Thymosin alpha 1 and immune modulation. Expert Opinion on Biological Therapy. 2018.
- Falutz J, et al. Effects of tesamorelin on visceral adipose tissue. New England Journal of Medicine. 2007;357(23):2359–2370.
This article is educational and reflects the published literature as of August 2026. It is not a diagnosis or a treatment recommendation for any individual, and any decision about your care belongs in a conversation with a licensed practitioner who has seen your history and your labs.